Human invariant NKT cells induce IL-1β secretion by peripheral blood monocytes via a P2X7-independent pathway

Journal of Immunology

Volumn 197, Issue 6, 2016, Pages 2455-2464

  Felley, Laura E ^a   Sharma, Akshat ^a   Theisen, Erin ^a   Romero Masters, James C ^a   Sauer, John Demian ^a   Gumperz, Jenny E ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CD69 ANTIGEN; CRYOPYRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 2; INTERLEUKIN 6; PURINERGIC P2X7 RECEPTOR; TOLL LIKE RECEPTOR; ADENOSINE TRIPHOSPHATE; ALARMIN; CYTOKINE; INFLAMMASOME; LIPOPOLYSACCHARIDE; NLRP3 PROTEIN, HUMAN; P2XR RECEPTOR, HUMAN;

ARTICLE; CELL ACTIVATION; CELL DEATH; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MONOCYTE; NATURAL KILLER T CELL; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS);

ADENOSINE TRIPHOSPHATE; ALARMINS; CASPASE 1; CYTOKINES; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; INTERLEUKIN-2; LIPOPOLYSACCHARIDES; MONOCYTES; NATURAL KILLER T-CELLS; NF-KAPPA B; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; RECEPTORS, PURINERGIC P2X7; SIGNAL TRANSDUCTION;

EID: 84988918009     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600790     Document Type: Article

References (51)

1. Brennan, P. J., M. Brigl, and M. B. Brenner. 2013. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol. 13: 101-117.
2. Fox, L. M., D. G. Cox, J. L. Lockridge, X.Wang, X. Chen, L. Scharf, D. L. Trott, R. M. Ndonye, N. Veerapen, G. S. Besra, et al. 2009. Recognition of lysophospholipids by human natural killer T lymphocytes. PLoS Biol. 7: e1000228.
3. Zhou, D., J. Mattner, C. Cantu, III, N. Schrantz, N. Yin, Y. Gao, Y. Sagiv, K. Hudspeth, Y. P. Wu, T. Yamashita, et al. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Science 306: 1786-1789.
4. Facciotti, F., G. S. Ramanjaneyulu, M. Lepore, S. Sansano, M. Cavallari, M. Kistowska, S. Forss-Petter, G. Ni, A. Colone, A. Singhal, et al. 2012. Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus. Nat. Immunol. 13: 474-480.
5. Kain, L., B. Webb, B. L. Anderson, S. Deng, M. Holt, A. Costanzo, M. Zhao, K. Self, A. Teyton, C. Everett, et al. 2014. The identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian a-linked glycosylceramides. [Published erratum appears in 2014 Immunity 41: 867.] Immunity 41: 543-554.
6. Liew, P. X., and P. Kubes. 2015. Intravital imaging-dynamic insights into natural killer T cell biology. Front. Immunol. 6: 240.
7. Geissmann, F., T. O. Cameron, S. Sidobre, N. Manlongat, M. Kronenberg, M. J. Briskin, M. L. Dustin, and D. R. Littman. 2005. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 3: e113.
8. Velázquez, P., T. O. Cameron, Y. Kinjo, N. Nagarajan, M. Kronenberg, and M. L. Dustin. 2008. Cutting edge: activation by innate cytokines or microbial antigens can cause arrest of natural killer T cell patrolling of liver sinusoids. J. Immunol. 180: 2024-2028.
9. Thomas, S. Y., S. T. Scanlon, K. G. Griewank, M. G. Constantinides, A. K. Savage, K. A. Barr, F. Meng, A. D. Luster, and A. Bendelac. 2011. PLZF induces an intravascular surveillance program mediated by long-lived LFA-1-ICAM-1 interactions. J. Exp. Med. 208: 1179-1188.
10. Hegde, S., L. Fox, X.Wang, and J. E. Gumperz. 2010. Autoreactive natural killer T cells: promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells. Immunology 130: 471-483.
11. Savage, A. K., M. G. Constantinides, J. Han, D. Picard, E. Martin, B. Li, O. Lantz, and A. Bendelac. 2008. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 29: 391-403.
12. Kovalovsky, D., O. U. Uche, S. Eladad, R. M. Hobbs,W. Yi, E. Alonzo, K. Chua, M. Eidson, H. J. Kim, J. S. Im, et al. 2008. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat. Immunol. 9: 1055-1064.
13. Bobryshev, Y. V., and R. S. Lord. 2002. Expression of heat shock protein-70 by dendritic cells in the arterial intima and its potential significance in atherogenesis. J. Vasc. Surg. 35: 368-375.
14. Bobryshev, Y. V., and R. S. Lord. 2005. Co-accumulation of dendritic cells and natural killer T cells within rupture-prone regions in human atherosclerotic plaques. J. Histochem. Cytochem. 53: 781-785.
15. Chan, W. L., N. Pejnovic, H. Hamilton, T. V. Liew, D. Popadic, A. Poggi, and S. M. Khan. 2005. Atherosclerotic abdominal aortic aneurysm and the interaction between autologous human plaque-derived vascular smooth muscle cells, type 1 NKT, and helper T cells. Circ. Res. 96: 675-683.
16. Melián, A., Y. J. Geng, G. K. Sukhova, P. Libby, and S. A. Porcelli. 1999. CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am. J. Pathol. 155: 775-786.
17. Kyriakakis, E., M. Cavallari, J. Andert, M. Philippova, C. Koella, V. Bochkov, P. Erne, S. B. Wilson, L. Mori, B. C. Biedermann, et al. 2010. Invariant natural killer T cells: linking inflammation and neovascularization in human atherosclerosis. Eur. J. Immunol. 40: 3268-3279.
18. Rogers, L., S. Burchat, J. Gage, M. Hasu, M. Thabet, L. Willcox, T. A. Ramsamy, and S. C. Whitman. 2008. Deficiency of invariant V alpha 14 natural killer T cells decreases atherosclerosis in LDL receptor null mice. [Published erratum appears in 2009 Cardiovasc. Res. 81: 814.] Cardiovasc. Res. 78: 167-174.
19. Wallace, K. L., M. A. Marshall, S. I. Ramos, J. A. Lannigan, J. J. Field, R. M. Strieter, and J. Linden. 2009. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-g and CXCR3 chemokines. Blood 114: 667-676.
20. Dinarello, C. A. 2011. A clinical perspective of IL-1b as the gatekeeper of inflammation. Eur. J. Immunol. 41: 1203-1217.
21. Zheng, Y., S. E. Gardner, and M. C. Clarke. 2011. Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 31: 2781-2786.
22. Brigl, M., P. van den Elzen, X. Chen, J. H. Meyers, D. Wu, C. H. Wong, F. Reddington, P. A. Illarianov, G. S. Besra, M. B. Brenner, and J. E. Gumperz. 2006. Conserved and heterogeneous lipid antigen specificities of CD1drestricted NKT cell receptors. J. Immunol. 176: 3625-3634.
23. Santos-Alvarez, J., R. Goberna, and V. Sánchez-Margalet. 1999. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell. Immunol. 194: 6-11.
24. Choi, A. J., and S. W. Ryter. 2014. Inflammasomes: molecular regulation and implications for metabolic and cognitive diseases. Mol. Cells 37: 441-448.
25. Lee, J., M. H. Rhee, E. Kim, and J. Y. Cho. 2012. BAY 11-7082 is a broadspectrum inhibitor with anti-inflammatory activity against multiple targets. Mediators Inflamm. 2012: 416036.
26. Coll, R. C., A. A. Robertson, J. J. Chae, S. C. Higgins, R. Munoz-Planillo, M. C. Inserra, I. Vetter, L. S. Dungan, B. G. Monks, A. Stutz, et al. 2015. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21: 248-255.
27. Ghonime, M. G., O. R. Shamaa, S. Das, R. A. Eldomany, T. Fernandes-Alnemri, E. S. Alnemri, M. A. Gavrilin, and M. D. Wewers. 2014. Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling and proteasome function. J. Immunol. 192: 3881-3888.
28. Dubyak, G. R. 2012. P2X7 receptor regulation of non-classical secretion from immune effector cells. Cell. Microbiol. 14: 1697-1706.
29. Khakh, B. S., and R. A. North. 2006. P2X receptors as cell-surface ATP sensors in health and disease. Nature 442: 527-532.
30. Pelegrin, P., and A. Surprenant. 2006. Pannexin-1 mediates large pore formation and interleukin-1b release by the ATP-gated P2X7 receptor. EMBO J. 25: 5071-5082.
31. Manthei, D. M., D. J. Jackson, M. D. Evans, R. E. Gangnon, C. J. Tisler, J. E. Gern, R. F. Lemanske, Jr., and L. C. Denlinger. 2012. Protection from asthma in a high-risk birth cohort by attenuated P2X7 function. J. Allergy Clin. Immunol. 130: 496-502.
32. Munoz-Planillo, R., P. Kuffa, G. Martínez-Colón, B. L. Smith, T. M. Rajendiran, and G. Núnez. 2013. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38: 1142-1153.
33. Pétrilli, V., S. Papin, C. Dostert, A. Mayor, F. Martinon, and J. Tschopp. 2007. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14: 1583-1589.
34. Gaidt, M. M., T. S. Ebert, D. Chauhan, T. Schmidt, J. L. Schmid-Burgk, F. Rapino, A. A. Robertson, M. A. Cooper, T. Graf, and V. Hornung. 2016. Human monocytes engage an alternative inflammasome pathway. Immunity 44: 833-846.
35. Shi, J., Y. Zhao, K. Wang, X. Shi, Y. Wang, H. Huang, Y. Zhuang, T. Cai, F. Wang, and F. Shao. 2015. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526: 660-665.
36. Kayagaki, N., I. B. Stowe, B. L. Lee, K. O'Rourke, K. Anderson, S. Warming, T. Cuellar, B. Haley, M. Roose-Girma, Q. T. Phung, et al. 2015. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526: 666-671.
37. Wang, X., X. Chen, L. Rodenkirch, W. Simonson, S. Wernimont, R. M. Ndonye, N. Veerapen, D. Gibson, A. R. Howell, G. S. Besra, et al. 2008. Natural killer T-cell autoreactivity leads to a specialized activation state. Blood 112: 4128-4138.
38. Yuan, W., S. J. Kang, J. E. Evans, and P. Cresswell. 2009. Natural lipid ligands associated with human CD1d targeted to different subcellular compartments. J. Immunol. 182: 4784-4791.
39. Cox, D., L. Fox, R. Tian, W. Bardet, M. Skaley, D. Mojsilovic, J. Gumperz, and W. Hildebrand. 2009. Determination of cellular lipids bound to human CD1d molecules. PLoS One 4: e5325.
40. López-Sagaseta, J., L. V. Sibener, J. E. Kung, J. Gumperz, and E. J. Adams. 2012. Lysophospholipid presentation by CD1d and recognition by a human natural killer T-cell receptor. EMBO J. 31: 2047-2059.
41. Salio, M., and V. Cerundolo. 2009. Linking inflammation to natural killer T cell activation. PLoS Biol. 7: e1000226.
42. Major, A. S., M. T. Wilson, J. L. McCaleb, Y. Ru Su, A. K. Stanic, S. Joyce, L. Van Kaer, S. Fazio, and M. F. Linton. 2004. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 24: 2351-2357.
43. Nakai, Y., K. Iwabuchi, S. Fujii, N. Ishimori, N. Dashtsoodol, K. Watano, T. Mishima, C. Iwabuchi, S. Tanaka, J. S. Bezbradica, et al. 2004. Natural killer T cells accelerate atherogenesis in mice. Blood 104: 2051-2059.
44. Tupin, E., A. Nicoletti, R. Elhage, M. Rudling, H. G. Ljunggren, G. K. Hansson, and G. P. Berne. 2004. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 199: 417-422.
45. Aslanian, A. M., H. A. Chapman, and I. F. Charo. 2005. Transient role for CD1drestricted natural killer T cells in the formation of atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 25: 628-632.
46. VanderLaan, P. A., C. A. Reardon, Y. Sagiv, L. Blachowicz, J. Lukens, M. Nissenbaum, C. R. Wang, and G. S. Getz. 2007. Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. Am. J. Pathol. 170: 1100-1107.
47. To, K., A. Agrotis, G. Besra, A. Bobik, and B. H. Toh. 2009. NKT cell subsets mediate differential proatherogenic effects in ApoE2/2 mice. Arterioscler. Thromb. Vasc. Biol. 29: 671-677.
48. Subramanian, S., M. S. Turner, Y. Ding, L. Goodspeed, S. Wang, J. H. Buckner, K. O'Brien, G. S. Getz, C. A. Reardon, and A. Chait. 2013. Increased levels of invariant natural killer T lymphocytes worsen metabolic abnormalities and atherosclerosis in obese mice. J. Lipid Res. 54: 2831-2841.
49. Li, Y., K. To, P. Kanellakis, H. Hosseini, V. Deswaerte, P. Tipping, M. J. Smyth, B. H. Toh, A. Bobik, and T. Kyaw. 2015. CD4+ natural killer T cells potently augment aortic root atherosclerosis by perforin-and granzyme B-dependent cytotoxicity. Circ. Res. 116: 245-254.
50. Bujak, M., and N. G. Frangogiannis. 2009. The role of IL-1 in the pathogenesis of heart disease. Arch. Immunol. Ther. Exp. (Warsz.) 57: 165-176.
51. Francis, S. E., N. J. Camp, R. M. Dewberry, J. Gunn, P. Syrris, N. D. Carter, S. Jeffery, J. C. Kaski, D. C. Cumberland, G. W. Duff, and D. C. Crossman. 1999. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 99: 861-866.